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Progression of Heart Failure
From AHA/ACC Stage A
to Stage B or Even C
Can We All Agree We Should Try
to Prevent This From Happening?*
Daniel J. Lenihan, MD
Nashville, Tennessee
Over the past decade, cardiology in general has dramatically
improved and enhanced the distribution of guidelines. The
scope of data and opinion that is summarized in these
various guidelines is nothing short of astounding. The
diagnosis and treatment of heart failure (HF) is one disease
area that has undergone extensive review, revision, and
updating with the end product being a definitive anthology
of what is known, and in part, what is not known, about the
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contemporary management of HF. Beginning in 2001, a
new classification of HF was introduced by the American
College of Cardiology and the American Heart Association
that included stage A (patients at high risk for the devel-
opment of HF) and stage B (patients with structural
abnormalities who are asymptomatic). Stage C patients had
current or past symptoms of HF, and then stage D had
evidence of refractory HF in need of specialized manage-
ment. This staging system was an expansion of the New
York Heart Association classification, and the stated pur-
pose was to “help healthcare providers identify patients early
who are at risk for the development of HF” (1). This more
inclusive staging system certainly achieves the goal of
improved identification, if one truly considers high-risk
conditions carefully. The next goal resulting from improved
identification would be to halt progression of HF to a higher
stage of disease.
In this issue of the Journal, Chen et al. (2) report on the
incidence of HF or cardiomyopathy (CM) that develops in
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received trastuzumab, anthracyclines, or both over a 3-year
period. Using the Surveillance, Epidemiology, and End
Results database for oncology, these researchers found a
significantly higher incidence of HF (treatment emergent)
in patients treated with trastuzumab or trastuzumab and
anthracyclines and lower incidence with anthracyclines
alone. These rates were compared with those of age-
matched and comorbidity-matched cancer patients not be-
ing treated with chemotherapy as well as those of cancer-
free Medicare patients.
The strengths of these data include the fact that the
dataset is inclusive, taking advantage of a national database
that collects diagnoses and treatment of a very broad
representation of cancer patients and that the authors
focused on a more elderly population that may not be fully
represented in a typical oncology treatment trial. There are
some inherent weaknesses as well that include the fact that
International Classification of Disease-9th Revision-
Clinical Modification coding was the method to confirm a
diagnosis of HF, not a careful prospective assessment that
used objective clinical criteria. Additionally, there were no
careful medication administration data that suggested which
treatments may be cardioprotective, such as angiotensin-
converting enzyme inhibitors or -blockers. If a patient was
taking these medications, this might have influenced the
treatment-emergent incidence of HF. Furthermore, mortal-
ity data were not provided that compared those in whom
HF developed with those who did not have HF, which
would have provided a window into the substantial impact
that HF has on overall outcome. Finally, it is somewhat
surprising that the vast majority of all the patients were not
treated with chemotherapy, which may suggest a reluctance
to provide aggressive treatment in older patients.
These issues notwithstanding, there are some very im-
portant lessons that can be learned from this report. First,
HF or CM are quite common in typical Medicare-age
breast cancer patients, occurring nearly 20% of the time over
a 3-year period. Second, trastuzumab and anthracycline
administration (alone or in combination) seriously raises the
risk and incidence of HF developing. Third, traditional
cardiovascular risk factors occur frequently in this popula-
tion and are important for the development of HF. For
instance, more than 50% of these patients had hypertension
and hyperlipidemia as well as other cardiovascular risks,
such as diabetes and atrial fibrillation, which occurred at a
lower, but not inconsequential, rate.
It is interesting that the initial unadjusted analysis sug-
gested that anthracyclines may be protective even for the
incidence of HF or CM, but after adjustments, a modest
increase risk for HF or CM was identified. One might
question the fact that, if no left ventricular function assess-
ment or other testing were performed, then an International
Classification of Disease-9th Revision-Clinical Modifica-
tion, diagnosis of HF or CM never would be recorded. It
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past anthracycline use is not commonly considered a major
risk for the development of HF in a typical cardiology or
oncology practice, and an assessment of left ventricular
function is not routinely performed. As a result, no diagno-
sis of HF or CM would be made in that case. Furthermore,
as soon as left ventricular dysfunction is identified, patients
do not seem to be treated optimally with cardiac medica-
tions, as frequently as we might expect (3). However,
trastuzumab initially was believed to greatly increase the risk
of HF or CM, and serial testing during treatment is widely
recommended and practiced, especially in research trials.
This may explain why trastuzumab had such a higher
treatment-emergent HF rate than anthracyclines, but gen-
erally this therapy is not considered to be as damaging as an
anthracycline. Another fascinating observation from these
data includes the fact that hyperlipidemia was protective for
the development of HF or CM. It could be theorized that
because hyperlipidemia was identified and presumably
treated, these patients likely were taking statin medications
that are protective against the progression of HF (4).
Further analysis of this concept is needed.
Overall, this analysis is very important, particularly in
understanding how common HF and CM are in cancer
patients and how substantially increased the incidence is
over 3 years in patients treated with chemotherapy. No
doubt trastuzumab, anthracyclines, and the combination
have to be considered as major risk factors for the develop-
ment of HF or CM, thus identifying a clear stage A HF
patient. Engaging providers, particularly cardiologists, in
the active management of cancer patients to prevent theirprogression from stage A HF to stage B or even stage C is
a calling we all must respond to because it may be occurring
in up to 20% of these cancer patients being treated with
certain chemotherapies (5). After all is said and done,
identification of HF or CM is only the first step. Prevention
and optimal management to delay progression of HF is the
real goal.
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